Skip to content
PeptideFactSheets
DiscontinuedModerate human evidence

Plain-English fact sheet

Lixisenatide

Also known as Adlyxin, Lyxumia, lixisenatide acetate

Diabetes and glucose controlNeurologic conditionsCognition and brain

Lixisenatide was approved in the United States for type 2 diabetes, but the Adlyxin products are listed as discontinued. A Phase 2 Parkinson study showed a motor signal with frequent gastrointestinal effects, not an approved neurologic use.

Quick answer

Lixisenatide is not FDA approved for Parkinson disease or neuroprotection. Its former U.S. Adlyxin products were approved for type 2 diabetes and are listed by FDA as discontinued; a small Phase 2 Parkinson trial needs larger confirmation.

By the PeptideFactSheets Editorial Team. Use the source links to verify status, evidence, risks, and unknowns; our editorial policyexplains the boundaries. Clinician review appears only when a named reviewer is shown.

What is Lixisenatide?

Lixisenatide is a peptide GLP-1 receptor agonist developed for glucose control in type 2 diabetes.

Interest in Parkinson disease comes from possible brain and inflammatory effects of GLP-1 signaling, not from the former diabetes approval.

Why are people interested in it?

The LIXIPARK trial reported less worsening on a motor score than placebo after one year.

That signal contrasts with a negative Phase 3 exenatide trial and makes replication, molecule differences, and study design especially important.

Current regulatory status

Discontinued

FDA records list the U.S. Adlyxin presentations as discontinued. The prior approval covered glycemic control in adults with type 2 diabetes, not Parkinson disease.

What is it approved for?

No FDA-approved use. This matters because clinical-trial participation and products marketed online are not the same as an approved medicine.

FDA approval path

Discontinued or stopped

U.S. product discontinued

Lixisenatide had an FDA-approved diabetes product, but the cited FDA product record and label context support treating the U.S. product as discontinued rather than currently marketed.

  1. DiscoveryBasic research
  2. PreclinicalLab and animal work
  3. Phase 1Initial human testing
  4. Phase 2Condition-focused trials
  5. Phase 3Confirmatory trials
  6. FDA reviewApplication review
  7. ApprovedLabel-specific use

This status sits outside the standard stepwise FDA drug-approval path.

Timeline source basis

FDA Purple Book: Adlyxin product statusFDA prescribing information: Adlyxin

What is it being studied for?

Type 2 diabetes
Early Parkinson disease
Motor disability progression
GLP-1 neurobiology

Investigational areas

  • Parkinson disease progression and neuroprotection

Evidence snapshot

Moderate human evidence

Diabetes efficacy was sufficient for the former approval. Parkinson evidence is limited to a relatively small Phase 2 trial with a motor-score signal, substantial gastrointestinal adverse effects, and no proof of disease modification.

Potential benefits being researched

  • LIXIPARK found less average worsening on the primary motor score than placebo over the controlled period.
  • The study was not large enough to establish routine treatment, long-term disease modification, or broad class efficacy.

Potential does not mean proven. Study design, population, endpoint, and regulatory review matter.

Known or possible risks

  • Nausea and vomiting were frequent in the Parkinson trial and affected tolerability.
  • The former diabetes label described pancreatitis, severe gastrointestinal reactions, kidney injury, hypoglycemia in some combinations, and hypersensitivity risks.
  • A discontinued commercial product and an investigational neurologic use create distinct access and evidence questions.

What we still do not know

  • Whether a larger confirmatory Parkinson trial will reproduce the motor signal
  • Whether the effect is symptomatic or disease modifying
  • Longer-term neurologic outcomes and tolerability
  • Why lixisenatide and exenatide trials produced different results

Plain-English takeaway

Lixisenatide offers a real Parkinson research signal, but not an approved neurologic treatment. The discontinued U.S. product, small trial, and tolerability burden all matter.

Research and reference links

Use these primary and reputable sources to verify status and read beyond this summary. Trial registries may list studies without proving a benefit.

  1. 1
    fdaFDA Purple Book: Adlyxin product status

    FDA record showing approval details and discontinued marketing status.

  2. 2
    fdaFDA prescribing information: Adlyxin

    Former diabetes indication, warnings, adverse reactions, and clinical evidence.

  3. 3
    pubmedLIXIPARK randomized Phase 2 trial

    Controlled early-Parkinson study reporting a motor-score signal and gastrointestinal adverse effects.